Argos Therapeutics (NASDAQ: ARGS) and Cardiome Pharma Corporation (NASDAQ:CRME) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Earnings & Valuation

This table compares Argos Therapeutics and Cardiome Pharma Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $485,347.00 20.33 -$44.47 million ($1.48) -0.12
Cardiome Pharma Corporation $23.21 million 3.10 -$17.41 million ($0.83) -2.57

Cardiome Pharma Corporation has higher revenue and earnings than Argos Therapeutics. Cardiome Pharma Corporation is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Argos Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Cardiome Pharma Corporation has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Argos Therapeutics and Cardiome Pharma Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 3 0 0 2.00
Cardiome Pharma Corporation 0 1 4 0 2.80

Argos Therapeutics currently has a consensus target price of $4.13, suggesting a potential upside of 2,202.69%. Cardiome Pharma Corporation has a consensus target price of $6.56, suggesting a potential upside of 208.10%. Given Argos Therapeutics’ higher possible upside, equities analysts plainly believe Argos Therapeutics is more favorable than Cardiome Pharma Corporation.

Insider and Institutional Ownership

27.9% of Argos Therapeutics shares are owned by institutional investors. Comparatively, 55.1% of Cardiome Pharma Corporation shares are owned by institutional investors. 28.2% of Argos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Argos Therapeutics and Cardiome Pharma Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -12,391.15% -1,532.49% -92.03%
Cardiome Pharma Corporation -110.95% -78.51% -38.30%

Summary

Cardiome Pharma Corporation beats Argos Therapeutics on 9 of the 13 factors compared between the two stocks.

About Argos Therapeutics

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

About Cardiome Pharma Corporation

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.